ImmunityBio Shares Tick Higher After Formal FDA Compliance Reply
ImmunityBio (NASDAQ: IBRX) saw its stock rise 3% on Monday after submitting a detailed response to the U.S. Food and Drug Administration addressing promotional compliance concerns tied to a television advertisement and a podcast. The company says the TV ad was never aired, removed the podcast from its site and requested third-party hosts take it do…